Logo

Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

Share this
Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

Shots:

  • The P-III CHOICE-01 trial evaluates toripalimab + CT vs CT alone in 465 patients in a ratio (2:1) with advanced sq./nonsq. NSCLC without driver mutations
  • The interim analysis met its 1EPs i.e.- improvement in PFS- superior ORR & DoR- OS data are still maturing. The safety profile was consistent with PD-1 inhibitor while final PFS & additional interim OS analyses are expected in later 2021
  • The companies plan to discuss with US FDA for submission of toripalimab’s BLA to treat NSCLC. The therapy has received FTD for mucosal melanoma- ODD for NPC- mucosal melanoma & soft tissue sarcoma- BTD for combination therapy as 1L treatment & for monothx. as 2L treatment of recurrent or metastatic NPC

  | Ref: Globe Newswire | Image: Coherus

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions